Livagen is a synthetic Lys‑Glu‑Asp‑Ala tetrapeptide that has been investigated for regulating liver function and immune cell activity, and it is currently used off‑label for those same purposes. In the community, the modal regimen is 1 mg taken each day, with users typically not specifying a particular time of day or cycling pattern. Because there is no FDA‑approved indication, all human use relies on compounding and off‑label practice, and no side effects have emerged as a consistent report—common injection‑site reactions and other typical peptide complaints have not been a recurring theme.
Data last updated
Measured on 4 of 6 axes
Evidence shape
Livagen currently exists as an animal-only research peptide with no published human clinical trials. The existing literature is restricted to preclinical and mechanistic research, providing no data on safety or efficacy in human subjects. Because there are no registered trials or completed human studies, the clinical profile remains entirely theoretical.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How LIVAGEN is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
One community user reports taking 1 mg subcutaneously, with no defined schedule or cycling.